GQD oral administration was found to alleviate the severity of colitis in DSS-induced mice model, with reduced toll-like receptor 4 expression and NF-κB activation, as well as decreased level of pro-inflammatory cytokines [24]. This evidence concerns the gene TLR4 and colitis.